[{"id":"paper-epcore-nhl-1-epcoritamab-jco-2023","kind":"paper","name":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","route":"/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/key-papers/blood-immune-cell.ts","type":"changed","fields":[{"field":"tldr","before":"\"An off-the-shelf bispecific antibody produced responses in 63% of patients with relapsed aggressive lymphoma, including many whose CAR-T had failed.\"","after":"\"In EPCORE NHL-1, the off-the-shelf bispecific antibody epcoritamab produced responses in 63% of patients with relapsed aggressive lymphoma, including many whose CAR-T had failed.\""}]},{"id":"paper-epcore-nhl-1-epcoritamab-jco-2023","kind":"paper","name":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","route":"/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/","commit":"65911992ce","date":"2026-09-08","author":"Jude Gomila","message":"Key papers: haematological malignancies and immune/cell therapy","file":"src/data/key-papers/blood-immune-cell.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"tldr"},{"field":"summary"},{"field":"journal"},{"field":"year"},{"field":"authors"},{"field":"paperType"},{"field":"findings"},{"field":"whatItMeans"},{"field":"caveats"},{"field":"changedPractice"},{"field":"participants"},{"field":"links"},{"field":"cancers"},{"field":"drugs"},{"field":"targets"},{"field":"technologies"},{"field":"trials"},{"field":"terms"},{"field":"companies"},{"field":"related"},{"field":"bottlenecks"}]}]